Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
ACS Med Chem Lett ; 12(11): 1794-1801, 2021 Nov 11.
Article in English | MEDLINE | ID: mdl-34795869

ABSTRACT

The PI3K/AKT/mTOR and PIM kinase pathways contribute to the development of several hallmarks of cancer. Cotargeting of these pathways has exhibited promising synergistic therapeutic effects in liquid and solid tumor types. To identify molecules with combined activities, we cross-screened our collection of PI3K/(±mTOR) macrocycles (MCXs) and identified the MCX thieno[3,2-d]pyrimidine derivative 2 as a moderate dual PI3K/PIM-1 inhibitor. We report the medicinal chemistry exploration and biological characterization of a series of thieno[3,2-d]pyrimidine MCXs, which led to the discovery of IBL-302 (31), a potent, selective, and orally bioavailable triple PI3K/mTOR/PIM inhibitor. IBL-302, currently in late preclinical development (AUM302), has recently demonstrated efficacy in neuroblastoma and breast cancer xenografts. Additionally, during the course of our experiments, we observed that macrocyclization was essential to obtain the desired multitarget profile. As a matter of example, the open precursors 35-37 were inactive against PIM whereas MCX 28 displayed low nanomolar activity.

2.
Front Oncol ; 4: 109, 2014.
Article in English | MEDLINE | ID: mdl-24860787

ABSTRACT

The PIM proteins, which were initially discovered as proviral insertion sites in Moloney-murine leukemia virus infection, are a family of highly homologous serine/threonine kinases that have been reported to be overexpressed in hematological malignancies and solid tumors. The PIM proteins have also been associated with metastasis and overall treatment responses and implicated in the regulation of apoptosis, metabolism, the cell cycle, and homing and migration, which makes these proteins interesting targets for anti-cancer drug discovery. The use of retroviral insertional mutagenesis and refined approaches such as complementation tagging has allowed the identification of myc, pim, and a third group of genes (including bmi1 and gfi1) as complementing genes in lymphomagenesis. Moreover, mouse modeling of human cancer has provided an understanding of the molecular pathways that are involved in tumor initiation and progression at the physiological level. In particular, genetically modified mice have allowed researchers to further elucidate the role of each of the Pim isoforms in various tumor types. PIM kinases have been identified as weak oncogenes because experimental overexpression in lymphoid tissue, prostate, and liver induces tumors at a relatively low incidence and with a long latency. However, very strong synergistic tumorigenicity between Pim1/2 and c-Myc and other oncogenes has been observed in lymphoid tissues. Mouse models have also been used to study whether the inhibition of specific PIM isoforms is required to prevent carcinogen-induced sarcomas, indicating that the absence of Pim2 and Pim3 greatly reduces sarcoma growth and bone invasion; the extent of this effect is similar to that observed in the absence of all three isoforms. This review will summarize some of the animal models that have been used to understand the isoform-specific contribution of PIM kinases to tumorigenesis.

3.
Bioorg Med Chem Lett ; 22(16): 5208-14, 2012 Aug 15.
Article in English | MEDLINE | ID: mdl-22819764

ABSTRACT

Phosphoinositide-3-kinases (PI3K) are a family of lipid kinases mediating numerous cell processes such as proliferation, migration and differentiation. PI3K is an important target for cancer therapeutics due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein, we describe the rapid identification of ETP-46992, within 2-aminocarbonyl imidazo [1,2-a] pyrazine series, with suitable pharmacokinetic (PK) properties that allows the establishment of mechanism of action and efficacy in vivo studies. ETP-46992 showed tumor growth inhibition in a GEMM mouse tumor model driven by a K-Ras(G12V) oncogenic mutation and in tumor xenograft models with PI3K pathway deregulated (BT474).


Subject(s)
Imidazoles/chemistry , Phosphoinositide-3 Kinase Inhibitors , Protein Kinase Inhibitors/chemistry , Pyrazines/chemistry , TOR Serine-Threonine Kinases/antagonists & inhibitors , Administration, Oral , Animals , Apoptosis/drug effects , Cell Line, Tumor , Cytochromes/metabolism , Disease Models, Animal , Half-Life , Humans , Imidazoles/chemical synthesis , Imidazoles/pharmacokinetics , Mice , Mice, Inbred BALB C , Microsomes, Liver/metabolism , Neoplasms/drug therapy , Phosphatidylinositol 3-Kinases/metabolism , Protein Kinase Inhibitors/pharmacokinetics , Protein Kinase Inhibitors/therapeutic use , Pyrazines/chemical synthesis , Pyrazines/pharmacokinetics , TOR Serine-Threonine Kinases/metabolism , Transplantation, Heterologous
4.
Bioorg Med Chem Lett ; 22(10): 3460-6, 2012 May 15.
Article in English | MEDLINE | ID: mdl-22520259

ABSTRACT

Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein, we describe the optimization of imidazo [1,2-a] pyrazines, which allow us to identify compound 14 (ETP-46321), with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after oral dosing. ETP-46321 PK/PD studies showed time dependent downregulation of AKT(Ser473) phosphorylation, which correlates with compound levels in tumor tissue and demonstrating to be efficacious in a GEMM mouse tumor model driven by a K-Ras(G12V) oncogenic mutation. Treatment with ETP-46321 resulted in significant tumor growth inhibition.


Subject(s)
Imidazoles/pharmacology , Isoenzymes/antagonists & inhibitors , Phosphoinositide-3 Kinase Inhibitors , Protein Kinase Inhibitors/pharmacology , Pyrazines/pharmacology , Administration, Oral , Biological Availability , Humans , Imidazoles/administration & dosage , Imidazoles/pharmacokinetics , Positron-Emission Tomography , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/pharmacokinetics , Pyrazines/administration & dosage , Pyrazines/pharmacokinetics , Tomography, X-Ray Computed
5.
Mitochondrion ; 12(1): 126-31, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21664300

ABSTRACT

The possible existence of a mitochondrially localized nitric oxide (NO) synthase (mtNOS) is controversial. To clarify this, we studied the ability of intact mitochondria to generate NO and the effect of mitochondrial NO on respiration. Respiratory rates and oxygen kinetics (P(50) values) were determined by high-resolution respirometry in skeletal-muscle mitochondria from control mice and mice injected with Escherichia coli lipopolysaccharide (LPS). In the presence of the NOS substrate L-arginine, mitochondria from LPS-treated mice had lower respiration rates and higher P(50) values than control animals. These effects were prevented by the NOS inhibitor L-NMMA. Our results suggest that mitochondrially derived NO is generated by an LPS-inducible NOS protein other than iNOS and modulates oxygen consumption in mouse skeletal muscle.


Subject(s)
Lipopolysaccharides/metabolism , Mitochondria, Muscle/drug effects , Mitochondria, Muscle/metabolism , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Nitric Oxide/metabolism , Animals , Cell Respiration , Escherichia coli/chemistry , Escherichia coli/immunology , Lipopolysaccharides/immunology , Mice , Mice, Inbred C57BL , Oxygen/metabolism
6.
Biochim Biophys Acta ; 1797(10): 1716-26, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20599679

ABSTRACT

The lipid peroxidation product 4-hydroxynonenal (HNE) increases the proton conductance of the inner mitochondrial membrane through effects on uncoupling proteins (UCPs) and the adenine nucleotide translocase (ANT); however, the relative contribution of the two carriers to these effects is unclear. To clarify this we isolated mitochondria from skeletal muscle and heart of wild-type and Ucp3 knockout (Ucp3KO) mice. To increase UCP3 expression, some mice were i.p. injected with LPS (12mg/kg body weight). In spite of the increased UCP3 expression levels, basal proton conductance did not change. HNE increased the proton conductance of skeletal muscle and heart mitochondria. In skeletal muscle, this increase was lower in Ucp3KO mice and higher in LPS-treated wild-type mice, and was partially abolished by GDP (UCPs inhibitor) and completely abolished by carboxyatractylate (ANT inhibitor) or addition of both inhibitors. GDP had no effect on HNE-induced conductance in heart mitochondria, but carboxyatractylate or administration of both inhibitors had a partial effect. GDP-mediated inhibition of HNE-activated proton conductance in skeletal muscle mitochondria was not observed in Ucp3KO mice, indicating that GDP is specific for UCP3, at least in muscle. Carboxyatractylate was able to inhibit UCP3, probably through an indirect mechanism. Our results are consistent with the conclusion that, in skeletal muscle, HNE-induced increase in proton conductance is mediated by UCP3 (30%) and ANT, whereas in the heart the increase is mediated by ANT and other carriers, possibly including UCP3.


Subject(s)
Aldehydes/pharmacology , Atractyloside/analogs & derivatives , Guanosine Diphosphate/pharmacology , Mitochondria/drug effects , Animals , Atractyloside/pharmacology , Blotting, Western , Cysteine Proteinase Inhibitors/pharmacology , Electron Transport Complex IV/metabolism , Female , Lipopolysaccharides/pharmacology , Male , Membrane Potential, Mitochondrial/drug effects , Mice , Mice, Inbred C57BL , Mice, Knockout , Mitochondria/metabolism , Mitochondria, Heart/drug effects , Mitochondria, Heart/metabolism , Mitochondria, Muscle/drug effects , Mitochondria, Muscle/metabolism , Mitochondrial ADP, ATP Translocases/metabolism , Muscle, Skeletal/metabolism , Oxygen Consumption/drug effects , Protons
7.
Biochim Biophys Acta ; 1797(5): 557-65, 2010 May.
Article in English | MEDLINE | ID: mdl-20144583

ABSTRACT

Nitric oxide (NO) inhibits mitochondrial respiration by decreasing the apparent affinity of cytochrome c oxidase (CcO) for oxygen. Using iNOS-transfected HEK 293 cells to achieve regulated intracellular NO production, we determined NO and O(2) concentrations and mitochondrial O(2) consumption by high-resolution respirometry over a range of O(2) concentrations down to nanomolar. Inhibition of respiration by NO was reversible, and complete NO removal recovered cell respiration above its routine reference values. Respiration was observed even at high NO concentrations, and the dependence of IC(50) on [O(2)] exhibits a characteristic but puzzling parabolic shape; both these features imply that CcO is protected from complete inactivation by NO and are likely to be physiologically relevant. We present a kinetic model of CcO inhibition by NO that efficiently predicts experimentally determined respiration at physiological O(2) and NO concentrations and under hypoxia, and accurately predicts the respiratory responses under hyperoxia. The model invokes competitive and uncompetitive inhibition by binding of NO to the reduced and oxidized forms of CcO, respectively, and suggests that dissociation of NO from reduced CcO may involve its O(2)-dependent oxidation. It also explains the non-linear dependence of IC(50) on O(2) concentration, and the hyperbolic increase of c(50) as a function of NO concentration.


Subject(s)
Electron Transport Complex IV/metabolism , Free Radical Scavengers/pharmacology , Nitric Oxide/physiology , Oxygen/metabolism , Cell Respiration , Cells, Cultured , Humans , Kidney/drug effects , Kidney/embryology , Kidney/enzymology , Kinetics , Mitochondria/drug effects , Mitochondria/metabolism , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Oxidation-Reduction , Oxygen Consumption
8.
Vet J ; 182(2): 301-5, 2009 Nov.
Article in English | MEDLINE | ID: mdl-18760641

ABSTRACT

An indirect fluorescent antibody (IFA) test is usually performed to detect antibodies in dogs naturally infected by Ehrlichia canis. In this work, results obtained using three different E. canis strains as antigen (a commercial antigen, the E. canis Oklahoma strain and the E. canis Madrid strain) were compared. One hundred and forty-nine serum samples obtained from dogs living in the centre of Spain were analysed. When qualitative results were evaluated, identical results were detected in 87.2% of samples for the three antigens tested. When comparing antibody titre results, differences between the Madrid strain and the commercial antigen, and between the Madrid and Oklahoma strains were statistically significant (P<0.0001). No differences were found when comparing the Oklahoma strain with the commercial antigen (P=0.562). Subtle intra-laboratory variations shown in this study suggest a higher sensitivity of the IFA test when an autochthonous strain is used as antigen.


Subject(s)
Dog Diseases/microbiology , Ehrlichia canis/isolation & purification , Ehrlichiosis/veterinary , Fluorescent Antibody Technique, Indirect/veterinary , Animals , Antibodies, Bacterial/blood , Antigens, Bacterial/chemistry , Dog Diseases/diagnosis , Dogs , Ehrlichiosis/diagnosis , Ehrlichiosis/microbiology , Fluorescent Antibody Technique, Indirect/methods , Spain , Statistics, Nonparametric
9.
Ann N Y Acad Sci ; 1149: 118-20, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19120188

ABSTRACT

The aim of this study was to compare different polymerase chain reaction (PCR) methods for the detection of Ehrlichia canis in blood samples and to relate these results to clinical findings and serology to E. canis using the indirect fluorescent antibody (IFA) test. Nine seropositive and nine seronegative dogs were included in this study. DNA was extracted once and used in one simple PCR and five nested PCR protocols previously described. In selected dogs (three seropositive and one seronegative) blood samples were aseptically collected in order to attempt the isolation of E. canis in the DH82 cell line. Results show that nested PCR protocols seem to be more sensitive than the simple PCR. Considering only nested PCR protocols, 33% of the IFA-positive samples were PCR positive using the five different protocols. The rest of the IFA-positive samples were PCR positive or negative depending on the protocol used. Clinical signs and laboratory findings compatible with canine monocytic ehrlichiosis (CME) were found in 67% of dogs positive by the IFA test. All samples positive by both techniques (IFA test and PCR) were from dogs suffering from clinical CME. IFA-negative samples were PCR negative, except 22% that were PCR positive when using only one of the nested PCR protocols. Isolation of the agent was exclusively achieved in the only case in which the IFA test and all the PCR protocols were also positive.


Subject(s)
Ehrlichia canis/isolation & purification , Ehrlichiosis/veterinary , Polymerase Chain Reaction/methods , Animals , DNA, Bacterial , Dogs , Ehrlichia canis/genetics , Ehrlichiosis/diagnosis , Fluorescent Antibody Technique
10.
J Vet Diagn Invest ; 19(6): 635-42, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17998551

ABSTRACT

An indirect enzyme-linked immunosorbent assay (ELISA) based on baculovirus recombinant P30 protein of Ehrlichia canis and the 1BH4 anticanine IgG monoclonal antibody was developed and evaluated by examining a panel of 98 positive and 157 negative sera using the indirect fluorescent antibody (IFA) test as the reference technique. The P30-based ELISA appeared to be sensitive and specific (77.55% and 95.54%, respectively) when qualitative results (positive/negative) were compared with those of the IFA test; the coefficient of correlation (R) between the 2 tests was 0.833. Furthermore, it was possible to establish a mathematical formula for use in comparing the results of both techniques. These results indicate that recombinant P30 antigen-based ELISA is a suitable alternative of the IFA test for simple, consistent, and rapid serodiagnosis of canine ehrlichiosis. Moreover, the use of this recombinant protein as antigen offers a great advantage for antigen preparation in comparison with other techniques in which the whole E. canis organism is used as antigen.


Subject(s)
Antibodies, Bacterial/blood , Antigens, Bacterial/blood , Dog Diseases/diagnosis , Ehrlichia canis/immunology , Ehrlichiosis/veterinary , Enzyme-Linked Immunosorbent Assay/veterinary , Animals , Antigens, Bacterial/genetics , Baculoviridae/genetics , Cloning, Molecular , Dog Diseases/blood , Dogs , Ehrlichiosis/blood , Ehrlichiosis/diagnosis , Fluorescent Antibody Technique, Indirect , Recombinant Proteins , Reproducibility of Results , Sensitivity and Specificity
11.
Biochem J ; 405(2): 223-31, 2007 Jul 15.
Article in English | MEDLINE | ID: mdl-17441787

ABSTRACT

Nitric oxide (NO) is a widespread biological messenger that has many physiological and pathophysiological roles. Most of the physiological actions of NO are mediated through the activation of sGC (soluble guanylate cyclase) and the subsequent production of cGMP. NO also binds to the binuclear centre of COX (cytochrome c oxidase) and inhibits mitochondrial respiration in competition with oxygen and in a reversible manner. Although sGC is more sensitive to endogenous NO than COX at atmospheric oxygen tension, the more relevant question is which enzyme is more sensitive at physiological oxygen concentration. Using a system in which NO is generated inside the cells in a finely controlled manner, we determined cGMP accumulation by immunoassay and mitochondrial oxygen consumption by high-resolution respirometry at 30 microM oxygen. In the present paper, we report that the NO EC50 of sGC was approx. 2.9 nM, whereas that required to achieve IC50 of respiration was 141 nM (the basal oxygen consumption in the absence of NO was 14+/-0.8 pmol of O2/s per 10(6) cells). In accordance with this, the NO-cGMP signalling transduction pathway was activated at lower NO concentrations than the AMPKs (AMP-activated protein kinase) pathway. We conclude that sGC is approx. 50-fold more sensitive than cellular respiration to endogenous NO under our experimental conditions. The implications of these results for cell physiology are discussed.


Subject(s)
Electron Transport Complex IV/physiology , Guanylate Cyclase/physiology , Mitochondria/physiology , Nitric Oxide/physiology , Oxygen Consumption/drug effects , Oxygen/physiology , AMP-Activated Protein Kinases , Cell Adhesion Molecules/metabolism , Cells, Cultured , Guanylate Cyclase/drug effects , Humans , Hydrazines/pharmacology , Microfilament Proteins/metabolism , Mitochondria/drug effects , Multienzyme Complexes/metabolism , Nitric Oxide Synthase Type II/metabolism , Phosphoproteins/metabolism , Phosphorylation , Protein Serine-Threonine Kinases/metabolism , Signal Transduction/drug effects
12.
J Wildl Dis ; 41(4): 810-5, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16456175

ABSTRACT

A wild injured Iberian lynx (Lynx pardinus) was taken from the Sierra Morena population. During the health check small intraerythrocytic piroplasms, morphologically indistinguishable from other feline piroplasms, were observed in Wright-Giemsa-stained blood films. Amplification by polymerase chain reaction of a portion of the 18S nuclear small subunit (NSS) rRNA gene and sequencing revealed similarity of the unknown organism with sequences obtained from Pallas's cat from Mongolia and from a domestic cat in Spain. In a retrospective (1993-2003) study of 50 Iberian lynx tissue samples, no amplifications of the 18S NSS rRNA gene of the organism were obtained. This is the first report of a naturally occurring erythroparasitemia in the Iberian lynx and the first documented case of naturally occurring piroplasm infection in a free-ranging felid from Europe.


Subject(s)
Babesia/isolation & purification , Babesiosis/veterinary , Erythrocytes/parasitology , Lynx , Protozoan Infections, Animal/epidemiology , Animals , Animals, Wild/parasitology , Babesia/classification , Babesiosis/epidemiology , DNA, Protozoan/chemistry , DNA, Ribosomal/chemistry , Lynx/parasitology , Male , Parasitemia/epidemiology , Parasitemia/veterinary , Phylogeny , Polymerase Chain Reaction/methods , Polymerase Chain Reaction/veterinary , RNA, Protozoan/genetics , RNA, Ribosomal/genetics , Spain/epidemiology
13.
Ann N Y Acad Sci ; 1026: 103-5, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15604476

ABSTRACT

Antibodies to Ehrlichia spp. and inclusion bodies compatible with Ehrlichia spp. in feline blood cells have been previously detected in Spain. The aim of this study was to assess the presence of antibodies to E. canis, N. risticii, and A. phagocytophilum in 122 feline serum samples from Madrid (central Spain). In addition, Ehrlichia genus-specific, one-tube, nested polymerase chain reaction (PCR) was performed from blood samples from these cats. Of the cats, 10.6% were seropositive for E. canis, 2.4% were positive for N. risticii, and 4.9% were seropositive for A. phagocytophilum. Two N. risticii-positive cats and one animal seropositive to A. phagocytophilum were also seropositive for E. canis. Despite these seropositive results, all the blood samples analyzed by PCR were negative. Our results demonstrate reactivity against agents implicated in feline ehrlichiosis in Spain. Further studies should be performed in order to clarify the significance of serology and PCR in the diagnosis of feline ehrlichiosis.


Subject(s)
Anaplasma phagocytophilum/genetics , Cat Diseases/microbiology , Ehrlichia canis/genetics , Ehrlichiosis/diagnosis , Ehrlichiosis/genetics , Anaplasma phagocytophilum/pathogenicity , Animals , Cat Diseases/genetics , Cats , DNA, Bacterial/analysis , Ehrlichia canis/pathogenicity , Polymerase Chain Reaction , Spain
14.
Ann N Y Acad Sci ; 1026: 154-7, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15604485

ABSTRACT

Northwestern Spain has traditionally been considered to be free from leishmaniasis. The aim of this work was to determine the prevalence of canine leishmaniasis in this area and to assess the influence of several risk factors on the incidence of this disease. A total of 479 dogs attended at different veterinary clinics in northwestern Spain were tested for L. infantum with the immunofluorescent antibody (IFA) test. The seroprevalence of L. infantum in this area was 3.7%. Most of the seropositive dogs lived in two locations: Valdcorras (seroprevalence of 29.2%) and Ourense (seroprevalence of 7.5%). The detection of high antibody titers in most of the seropositive dogs (many of which presented clinical signs) coupled with the certainity that some of these dogs had never been outside their home areas indicates the presence of this zoonosis in these two sites. On the other hand, companion dogs were significantly less likely to acquire the disease than sheep dogs, hunting dogs, and those from kennels.


Subject(s)
Dog Diseases/epidemiology , Dog Diseases/immunology , Leishmania infantum/pathogenicity , Leishmaniasis, Visceral/epidemiology , Leishmaniasis, Visceral/veterinary , Animals , Dogs , Female , Fluorescent Antibody Technique, Direct/veterinary , Leishmania infantum/immunology , Male , Seroepidemiologic Studies , Spain/epidemiology
15.
Vet Parasitol ; 125(3-4): 365-72, 2004 Nov 10.
Article in English | MEDLINE | ID: mdl-15482892

ABSTRACT

This paper reports the first isolation and culture of Ehrlichia canis in Spain from a naturally infected dog using the DH82 cell line. After DNA extraction and PCR amplification, a nearly complete (1412bp) sequence of the 16S rRNA gene of the new E. canis strain was obtained. The GenBank accession number for the nucleotide sequence of this strain is AY394465. This sequence was aligned with the 16S rRNA gene sequences of other Ehrlichia strains accessible in GenBank. The 16S rRNA gene sequence of the E. canis strain reported here showed a high percentage of similarity with the 16S rRNA gene sequence of E. canis from different geographic areas including Japan, Venezuela and Israel. These data confirm the presence of E. canis in Spain.


Subject(s)
Dog Diseases/parasitology , Ehrlichia canis/genetics , Ehrlichia canis/isolation & purification , Ehrlichiosis/parasitology , Ehrlichiosis/veterinary , Imidocarb/analogs & derivatives , Animals , Antibodies, Protozoan/blood , Antiprotozoal Agents/therapeutic use , Base Sequence , DNA, Protozoan/chemistry , DNA, Protozoan/genetics , Dog Diseases/drug therapy , Dogs , Ehrlichiosis/drug therapy , Fatal Outcome , Female , Fluorescent Antibody Technique, Indirect/veterinary , Imidocarb/therapeutic use , Molecular Sequence Data , Phylogeny , Polymerase Chain Reaction/veterinary , Sequence Alignment , Spain
SELECTION OF CITATIONS
SEARCH DETAIL
...